Comparative Pharmacology
Head-to-head clinical analysis: EDURANT versus EDURANT PED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDURANT versus EDURANT PED.
EDURANT vs EDURANT PED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to HIV-1 reverse transcriptase, causing conformational changes that inhibit enzyme activity and viral replication.
Edurant PED is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. It binds to reverse transcriptase, causing a conformational change that inhibits the enzyme's RNA-dependent and DNA-dependent DNA polymerase activities, thereby blocking viral replication.
25 mg orally once daily with a meal.
25 mg orally once daily with a meal.
None Documented
None Documented
Terminal half-life 38 hours (range 25-57 h); supports once-daily dosing, steady state at ~7 days
Terminal elimination half-life is approximately 50 hours (range 34-73 h). This long half-life supports once-daily dosing and allows for sustained plasma concentrations.
Renal (~25% unchanged) and fecal (~60% as metabolites); total recovery ~85%
Rilpivirine is primarily metabolized by CYP3A4; after oral administration, approximately 85% of the dose is recovered in feces (mainly as unchanged drug and metabolites) and 6% in urine. Less than 1% is excreted unchanged in urine.
Category C
Category C
NNRTI Antiretroviral
NNRTI Antiretroviral